Latest news with #ADDF
Yahoo
5 days ago
- Business
- Yahoo
Leonard Lauder, former CEO of beauty empire Estée Lauder, dies at 92
Leonard Lauder, CEO emeritus of the multibillion-dollar Estée Lauder beauty empire founded by his parents and named after his mother, has died. He was 92. The Estée Lauder Companies Inc. announced his death Sunday 'with deep sadness' and said Lauder, the eldest son of Estée and Joseph Lauder, had died at home 'surrounded by family.' The New York City native graduated from the Bronx High School of Science and studied business at Columbia University, among other prominent schools, the company said. After formally joining the family business in 1958, he expanded the single brand 'handful of products' into a global beauty empire during six decades at the company. He served as president from 1972-1995, as CEO from 1982-1999, and as chairman from 1995 through June 2009, and was 'deeply involved' in company acquisition strategy until his death. The 'true visionary, fearless leader, and cherished friend to so many' was 'the beacon of our company and the north star of an entire industry,' the company said. 'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William Lauder, his son and the current chairman of Estée Lauder's board of directors. 'Above all, my father was a man who practiced kindness with everyone he met. His impact was enormous.' Lauder was known as much for his philanthropy as for his business acumen, and championed health causes such as Alzheimer's disease and breast cancer. He pledged $1 billion in Cubist works to the Metropolitan Museum of Art, donated $125 million to the University of Pennsylvania School of Nursing and gave $10 million to Hunter College's nursing school in New York City. Lauder helped his late wife Evelyn Lauder launch the famous Pink Ribbon campaign, an awareness initiative of the Breast Cancer Research Foundation, which she founded in 1993. In 1998, Lauder and his brother Ronald Lauder co-founded the Alzheimer's Drug Discovery Foundation, which 'reshaped the Alzheimer's research landscape,' ADDF co-founder and chief science officer Dr. Howard Fillit said, adding that 'Lauder's legacy is woven into the very fabric of the ADDF and the progress it has driven toward understanding, treating, and ultimately curing Alzheimer's.' ___________
Malaysian Reserve
6 days ago
- Business
- Malaysian Reserve
Statement from the Alzheimer's Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder
The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ — It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co-Founder and Chairman, Leonard A. Lauder. A visionary philanthropist, cosmetics industry icon, and steadfast champion in the fight against Alzheimer's disease, Lauder's legacy is woven into the very fabric of the ADDF and the progress it has driven toward understanding, treating, and ultimately curing Alzheimer's. 'Leonard Lauder was a once-in-a-generation visionary whose leadership, along with his brother Ronald, reshaped the Alzheimer's research landscape,' said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. 'From the very beginning, Leonard understood that Alzheimer's does not just impact the patient, it affects entire families. The Lauder family recognized the emotional, financial, and societal toll of this disease, and built the ADDF to accelerate the discovery and development of treatments that could change the trajectory for patients and their loved ones. Leonard's vision, generosity, and humanity spanned across his business acumen to his philanthropic endeavors, touching countless lives, and his legacy will endure in every breakthrough we help bring forward.' Lauder and his brother, Ronald S. Lauder, co-founded the ADDF in 1998 with Dr. Fillit in honor of their mother, Estee Lauder's, battle with Alzheimer's. At a time when Alzheimer's research funding was sparse and interest from the private sector limited, the Lauder family recognized the urgent need for treatments and created a bold new venture philanthropy model to achieve this mission, combining the rigor of scientific research with the agility and entrepreneurialism of venture capital. For over more than 27 years, the Lauders' leadership helped shape the ADDF into the world's leading philanthropic funder of drug discovery and development research. Under the Lauders' guidance, the ADDF has: Invested more than $370 million into over 765 drug discovery programs across 21 countries Catalyzed more than $3 billion in follow-on funding from pharmaceutical companies, venture capital firms, and government agencies, helping to de-risk early-stage science and attract broader investment into Alzheimer's research Played a pivotal role in the development of the first biomarkers for Alzheimer's by providing early seed funding for Amyvid, the first FDA-approved PET scan for Alzheimer's; PrecivityAD, the first Alzheimer's blood test to market; and Lumipulse, the first Alzheimer's blood test to receive FDA approval Established the Diagnostics Accelerator (DxA) in partnership with Bill Gates and other visionary philanthropists to advance affordable, accessible diagnostic tools, a critical step toward earlier detection and intervention Advanced a diverse pipeline of treatments by pioneering the biology of aging approach, now central to the field, with over 70% of drugs targeting disease pathways such as inflammation, neuroprotection, vascular health, and synaptic function, paving the way for Alzheimer's to be treated with combination therapy and precision medicine, as in cancer Brought forward a precision prevention approach, combining lifestyle interventions and therapeutics to slow the progression or prevent the onset of Alzheimer's altogether Through all these achievements, Lauder and his family remained deeply committed to the ADDF's mission. 'Leonard's impact on the ADDF, and on the field of Alzheimer's research more broadly, is immeasurable,' said Mark Roithmayr, Chief Executive Officer of the ADDF. 'He brought a sense of urgency to this work that pushed us all to do more and move faster. He believed that patients and families deserve better and he committed himself fully to building a world in which effective treatments are not only possible, but inevitable. His leadership, his generosity, and his humanity will continue to guide the ADDF's mission every day.' Lauder's impact extended across business, culture, and philanthropy. Yet for those who worked alongside him at the ADDF, he will be remembered most for his compassion, clarity of purpose, and unwavering belief in progress. He understood that Alzheimer's is a deeply human and societal challenge, one affecting memory, identity, and dignity. The ADDF honors Lauder's legacy by reaffirming our commitment to conquer Alzheimer's for the millions of patients and families living with this devastating disease. About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit:
Yahoo
6 days ago
- Business
- Yahoo
Statement from the Alzheimer's Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder
The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ -- It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co-Founder and Chairman, Leonard A. Lauder. A visionary philanthropist, cosmetics industry icon, and steadfast champion in the fight against Alzheimer's disease, Lauder's legacy is woven into the very fabric of the ADDF and the progress it has driven toward understanding, treating, and ultimately curing Alzheimer's. "Leonard Lauder was a once-in-a-generation visionary whose leadership, along with his brother Ronald, reshaped the Alzheimer's research landscape," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "From the very beginning, Leonard understood that Alzheimer's does not just impact the patient, it affects entire families. The Lauder family recognized the emotional, financial, and societal toll of this disease, and built the ADDF to accelerate the discovery and development of treatments that could change the trajectory for patients and their loved ones. Leonard's vision, generosity, and humanity spanned across his business acumen to his philanthropic endeavors, touching countless lives, and his legacy will endure in every breakthrough we help bring forward." Lauder and his brother, Ronald S. Lauder, co-founded the ADDF in 1998 with Dr. Fillit in honor of their mother, Estee Lauder's, battle with Alzheimer's. At a time when Alzheimer's research funding was sparse and interest from the private sector limited, the Lauder family recognized the urgent need for treatments and created a bold new venture philanthropy model to achieve this mission, combining the rigor of scientific research with the agility and entrepreneurialism of venture capital. For over more than 27 years, the Lauders' leadership helped shape the ADDF into the world's leading philanthropic funder of drug discovery and development research. Under the Lauders' guidance, the ADDF has: Invested more than $370 million into over 765 drug discovery programs across 21 countries Catalyzed more than $3 billion in follow-on funding from pharmaceutical companies, venture capital firms, and government agencies, helping to de-risk early-stage science and attract broader investment into Alzheimer's research Played a pivotal role in the development of the first biomarkers for Alzheimer's by providing early seed funding for Amyvid, the first FDA-approved PET scan for Alzheimer's; PrecivityAD, the first Alzheimer's blood test to market; and Lumipulse, the first Alzheimer's blood test to receive FDA approval Established the Diagnostics Accelerator (DxA) in partnership with Bill Gates and other visionary philanthropists to advance affordable, accessible diagnostic tools, a critical step toward earlier detection and intervention Advanced a diverse pipeline of treatments by pioneering the biology of aging approach, now central to the field, with over 70% of drugs targeting disease pathways such as inflammation, neuroprotection, vascular health, and synaptic function, paving the way for Alzheimer's to be treated with combination therapy and precision medicine, as in cancer Brought forward a precision prevention approach, combining lifestyle interventions and therapeutics to slow the progression or prevent the onset of Alzheimer's altogether Through all these achievements, Lauder and his family remained deeply committed to the ADDF's mission. "Leonard's impact on the ADDF, and on the field of Alzheimer's research more broadly, is immeasurable," said Mark Roithmayr, Chief Executive Officer of the ADDF. "He brought a sense of urgency to this work that pushed us all to do more and move faster. He believed that patients and families deserve better and he committed himself fully to building a world in which effective treatments are not only possible, but inevitable. His leadership, his generosity, and his humanity will continue to guide the ADDF's mission every day." Lauder's impact extended across business, culture, and philanthropy. Yet for those who worked alongside him at the ADDF, he will be remembered most for his compassion, clarity of purpose, and unwavering belief in progress. He understood that Alzheimer's is a deeply human and societal challenge, one affecting memory, identity, and dignity. The ADDF honors Lauder's legacy by reaffirming our commitment to conquer Alzheimer's for the millions of patients and families living with this devastating disease. About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: View original content to download multimedia: SOURCE Alzheimer's Drug Discovery Foundation
![Life Molecular Imaging Secures Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Further Investigate [18F]F-DED PET in Alzheimer's Neuroinflammation](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fapnews.com.png&w=48&q=75){kind=small}
Associated Press
20-05-2025
- Health
- Associated Press
Life Molecular Imaging Secures Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Further Investigate [18F]F-DED PET in Alzheimer's Neuroinflammation
Joining forces to accelerate development and to create a potential new option for Neuroinflammation Imaging BERLIN and BOSTON, May 20, 2025 /PRNewswire/ -- Life Molecular Imaging has received an investment from the Alzheimer's Drug Discovery Foundation (ADDF) to advance significant research in Alzheimer's disease (AD). The $2.16 million investment, spanning three years, will fuel the development of [18F]F‑DED, an investigational F18-labeled PET imaging agent designed to target monoamine oxidase B (MAO-B), a key enzyme linked to neuroinflammation. This ambitious research initiative is a collaborative effort with two world-class institutions, including the University Hospital of Ludwig-Maximilian University (LMU; Munich, Germany) and the Barcelona Beta Brain Research Center (BBRC, Spain), with experts in neurology, nuclear medicine, psychiatry, and stroke and dementia research. It is anticipated that using [18F]F-DED PET imaging during this project has the potential to provide critical insights into both sporadic and genetically predisposed AD patients, bridging the gap on the contribution of neuroinflammation between early and late stages of the disease. Until now, PET imaging of neuroinflammation has faced challenges due to genetic polymorphisms affecting ligand binding, leading to inconsistent results. 'This new research, supported by the prestigious ADDF funding, provides a unique opportunity to investigate the spatial and temporal dynamics of neuroinflammation and its association with established biomarkers,' said Andrew Stephens, Chief Medical Officer at LMI. 'Neuroinflammation could be a potential key driver in the spread of tau pathology to the cortex in Alzheimer's disease. Leveraging PET imaging to explore its role presents a unique opportunity to deepen our understanding of disease progression,' added Matthias Brendel, Professor for Nuclear Medicine at LMU. Gemma Salvadó Blasco, Group Leader of Neuroimaging Research BBRC, echoed this enthusiasm: 'By combining data from diverse Alzheimer's disease cohorts, we aim to unravel the complexities of disease progression. We're thrilled to embark on this exciting journey.' 'PET-Imaging tools provide important insights into understanding Alzheimer's disease and other neurodegenerative disorders and are integrated now into clinical care,' says Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. 'New imaging tools exploring neuroinflammation may offer a non-invasive approach to visualize astrocyte activity alongside established biomarkers to further examine the relationship between inflammation and Alzheimer's. If successful, this innovative approach will help deepen our understanding of the underlying disease.' About Neuroinflammation represents a key pathologic mechanism in many neurodegenerative diseases, including AD, movement disorders and multiple sclerosis. In the brain it can be mediated by reactive astrocytes (astrogliosis), which show increased activity of the enzyme monoamine oxidase B (MAO-B). The PET tracer [18F]F-DED is a deuterated deprenyl derivative that was designed to preferentially bind to areas with increased MAO-B activity (1,2). About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI) is an international radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit About Life Healthcare Group Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: References 1. Nag S, Fazio P, Lehmann L, et al. In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl. J Nucl Med. 2016;57(2):315-320. doi:10.2967/jnumed.115.161083 2. Ballweg A, Klaus C, Vogler L, et al. [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data. J Neuroinflammation. 2023;20(1):68. Published 2023 Mar 11. doi:10.1186/s12974-023-02749-2 For media queries Brittany Hahn | Marketing Communications Manager | Life Molecular Imaging Tel: +1.484.735.2840 | [email protected] For scientific information, please contact: Dr. Gérard N Bischof, PD | Scientific Project Manager | Life Molecular Imaging| [email protected] View original content to download multimedia: SOURCE Life Molecular Imaging
Yahoo
20-05-2025
- Health
- Yahoo
Life Molecular Imaging Secures Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Further Investigate [18F]F-DED PET in Alzheimer's Neuroinflammation
Joining forces to accelerate development and to create a potential new option for Neuroinflammation Imaging BERLIN and BOSTON, May 20, 2025 /PRNewswire/ -- Life Molecular Imaging has received an investment from the Alzheimer's Drug Discovery Foundation (ADDF) to advance significant research in Alzheimer's disease (AD). The $2.16 million investment, spanning three years, will fuel the development of [18F]F‑DED, an investigational F18-labeled PET imaging agent designed to target monoamine oxidase B (MAO-B), a key enzyme linked to neuroinflammation. This ambitious research initiative is a collaborative effort with two world-class institutions, including the University Hospital of Ludwig-Maximilian University (LMU; Munich, Germany) and the Barcelona Beta Brain Research Center (BBRC, Spain), with experts in neurology, nuclear medicine, psychiatry, and stroke and dementia research. It is anticipated that using [18F]F-DED PET imaging during this project has the potential to provide critical insights into both sporadic and genetically predisposed AD patients, bridging the gap on the contribution of neuroinflammation between early and late stages of the disease. Until now, PET imaging of neuroinflammation has faced challenges due to genetic polymorphisms affecting ligand binding, leading to inconsistent results. "This new research, supported by the prestigious ADDF funding, provides a unique opportunity to investigate the spatial and temporal dynamics of neuroinflammation and its association with established biomarkers," said Andrew Stephens, Chief Medical Officer at LMI. "Neuroinflammation could be a potential key driver in the spread of tau pathology to the cortex in Alzheimer's disease. Leveraging PET imaging to explore its role presents a unique opportunity to deepen our understanding of disease progression," added Matthias Brendel, Professor for Nuclear Medicine at LMU. Gemma Salvadó Blasco, Group Leader of Neuroimaging Research BBRC, echoed this enthusiasm: "By combining data from diverse Alzheimer's disease cohorts, we aim to unravel the complexities of disease progression. We're thrilled to embark on this exciting journey." "PET-Imaging tools provide important insights into understanding Alzheimer's disease and other neurodegenerative disorders and are integrated now into clinical care," says Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. "New imaging tools exploring neuroinflammation may offer a non-invasive approach to visualize astrocyte activity alongside established biomarkers to further examine the relationship between inflammation and Alzheimer's. If successful, this innovative approach will help deepen our understanding of the underlying disease." AboutNeuroinflammation represents a key pathologic mechanism in many neurodegenerative diseases, including AD, movement disorders and multiple sclerosis. In the brain it can be mediated by reactive astrocytes (astrogliosis), which show increased activity of the enzyme monoamine oxidase B (MAO-B). The PET tracer [18F]F-DED is a deuterated deprenyl derivative that was designed to preferentially bind to areas with increased MAO-B activity (1,2). About Life Molecular Imaging (LMI)Life Molecular Imaging (LMI) is an international radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit About Life Healthcare GroupLife Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: References 1. Nag S, Fazio P, Lehmann L, et al. In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl. J Nucl Med. 2016;57(2):315-320. doi:10.2967/jnumed.115.161083 2. Ballweg A, Klaus C, Vogler L, et al. [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data. J Neuroinflammation. 2023;20(1):68. Published 2023 Mar 11. doi:10.1186/s12974-023-02749-2 For media queriesBrittany Hahn | Marketing Communications Manager | Life Molecular ImagingTel: +1.484.735.2840 | For scientific information, please contact: Dr. Gérard N Bischof, PD | Scientific Project Manager | LifeMolecular Imaging| View original content to download multimedia: SOURCE Life Molecular Imaging Sign in to access your portfolio
